DCF方案联合扶正和胃汤治疗进展期胃癌34例临床观察

作者	单位
王洪真	山东省日照市中医医院肿瘤科
王海滨	山东省日照市中医医院肿瘤科
高宏	山东省日照市中医医院肿瘤科
屈中玉	河南省南阳市中心医院肿瘤科
刘浩	中国中医科学院广安门中医院肿瘤科

摘要点击次数: 1354

全文下载次数: 3

中文摘要:

目的观察中西医结合治疗进展期胃癌的疗效和不良反应。方法将66例进展期胃癌患者随机分成两组。治疗组34例用中药加DCF方案化疗,对照组32例单纯用DCF方案化疗。结果治疗组和对照组有效率分别为55.9%和50.0%,临床受益率分别为85.3%和81.3%,均无统计学差异;半年生存率:治疗组为82.4%,对照组为65.6%,两组比较无显著性差异(P>0.05);1年生存率:治疗组为52.9%,对照组为25.0%,两组结果有显著性差异(P<0.05)。两组不良反应:WBC下降、恶心呕吐、黏膜反应、乏力有差异性(P<0.05)。结论中西医结合治疗进展期胃癌虽未能明显改善近期疗效,但能减轻不良反应,改善患者生活质量,延长患者生存期。

英文摘要:

Objective To evaluate the therapeutic and adverse reactions of integrative Chinese and Western medicine (ICWM) for treatment of advanced gastric carcinoma. Methods Sixty-six patients with advanced gastric carcinoma were randomized into two groups. Patients in the treatment group (34 patients) received chemotherapy of DCF (docetaxel/cisplatin/5-fluorouracil) regimen combined with Chinese herbal medicine, and patients in the control group (32 patients) were treated with chemotherapy of the same regimen alone. Results No significant difference between the two groups was found in response rate (55.9% versus 50.0%), clinical benefiting rate (85.3% versus 81.3%) and half year survival rate (82.4% versus 65.6%); but the 1-year survival rate in the treatment group was superior to that in the control group (52.9% versus 25.0%, P<0.05). As for the adverse reactions, significant difference between the two groups was shown in incidence of leucopenia, nausea and vomiting, mucosa reaction and fatigue, these reactions occurred lesser in the treatment group (P<0.05). Conclusion Although treatment of ICWM for advanced gastric carcinoma cannot improve response rate, it could alleviate the adverse reactions of the treatment, improve quality of life and prolong the survival rate in patients.

关闭